# MEDICAMEN Organics Limited

**Regd. & Corporate Office:** 10, Community Centre No.2, Ashok Vihar Phase-II, Delhi-110052 (India)
**Tel:** 011-27430249, 27138171
**E-mail:** info@mediorganics.in | **CIN No:** L74899DL1995PLC066416 | **GSTIN:**07AABCM4302P1ZF

**January 09, 2025**

To,
**National Stock Exchange of India Limited**
**Listing & Compliance Department**
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai, 400051, Maharashtra, India.

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

**Subject: Press Release - Medicamen Organics Raises ₹ 3 Cr through Convertible Warrants Issue**

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled - **"Medicamen Organics Raises ₹ 3 Cr through Convertible Warrants Issue".**

A copy of the same will also be uploaded on the Company's website www.medicamenorganics.com.

Kindly take the same on record and display the same on the website of your exchange.

Thanking you.

Yours faithfully,

**For and on behalf of**
**Medicamen Organics Limited**

Ashutosh Gupta
Digitally signed by Ashutosh Gupta
DN: cn=Ashutosh Gupta, o, ou, email=jan@gmail.com, c=IN
Date: 2025.01.09 19:38:33 +05'30'

**Ashutosh Gupta**
**Whole-time Director**
**DIN: 00039995**

**Place: New Delhi**

**Encl.:** as stated above

# Medicamen Organics Raises ₹ 3 Cr Through Convertible Warrants Issue

**New Delhi, January 09, 2025 – Medicamen Organics Limited (MOL) (NSE- MEDIORG)** one of the leading manufacturers of pharmaceutical and health products, has announced the issuance and allotment of 4,65,910 convertible warrants on a preferential basis to the promoter group of the company. This move aims to raise ₹ 3 Cr, which will be utilized to strengthen the company's working capital.

The convertible warrants are priced at ₹64.39 each, including a premium of ₹54.39 per share. Each warrant grants the holder the right to convert it into one fully paid-up equity share of ₹10 face value within 18 months from the date of allotment. Following the allotment, the promoters' holding in the company will increase to 61.24% from the current 59.69%.

This strategic initiative highlights Medicamen Organics Limited's commitment to fuelling its growth plans by ensuring sufficient capital for its day-to-day activities. The funds raised will bolster the company's operational capacity and support its efforts to cater to increasing market demands.

**Commenting on the collaboration, Mr. Bal Kishan Gupta, Managing Director said,** "We are pleased to announce this preferential allotment of convertible warrants to the promoter group, which will provide us with the necessary capital to support our ongoing projects. These initiatives are aligned with our growth strategy, and the funds raised will enable us to strengthen our working capital without impacting any of our existing working capital arrangements.

With this financial backing, we aim to accelerate project execution and drive better growth in the coming quarters. We remain committed to delivering value to our stakeholders while advancing our position as a trusted player in the pharmaceutical and healthcare sector."

## About Medicamen Organics Limited

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 25.29 Cr, with EBITDA of ₹ 4.76 Cr & PAT of ₹ 2.62 Cr.

## Disclaimer

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

## For Further Information Please Contact Corporate Communication Advisor


| | |
|---|---|
| Kirin Advisors | **Kirin Advisors Private Limited**<br>Sunil Mudgal – Director<br>sunil@kirinadvisors.com<br>+91 98692 75849<br>www.kirinadvisors.com |